Literature DB >> 8027271

Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis.

S G Hillier1.   

Abstract

Around 400 follicles sequentially mature and ovulate during an average woman's reproductive lifetime. From birth to the menopause, the other approximately 99.98% of her follicles begin development but never complete it. Instead they default to atresia due to inadequate stimulation by follicle stimulating hormone (FSH). Follicular growth to the stage of antrum formation (approximately 0.25 mm diameter) is independent of gonadotrophic stimulation. Antrum formation and further growth to the stage at which follicles become potentially able to begin preovulatory development (2-5 mm diameter) require tonic stimulation by FSH. Before onset of puberty, blood concentrations of FSH do not rise sufficiently to sustain development beyond this stage, therefore all antral follicles become atretic. After puberty, as each menstrual cycle begins, FSH concentrations rise beyond a critical 'threshold' and multiple follicles are recruited to begin pre-ovulatory development. Due to increases in its responsiveness to FSH and luteinizing hormone (LH), one of these follicles becomes selected to ovulate while the remainder become atretic. At mid-follicular phase, the dominant follicle reaches > or = 10 mm in diameter and increasingly synthesizes oestradiol. Tonic stimulation by FSH and LH, underpinned by local paracrine signalling, maintains oestrogen secretion by the dominant follicle, which grows to > or = 20 mm in diameter before it ovulates in response to the mid-cycle LH surge. The development-related response to LH shown by the pre-ovulatory follicle raises the possibility that exogenous LH might be used as an adjunct to therapy with exogenous FSH in clinical ovulation induction regimens where the aim is to induce monovulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027271     DOI: 10.1093/oxfordjournals.humrep.a138480

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  64 in total

1.  Improved pregnancy rates with luteinizing hormone supplementation in patients undergoing ovarian stimulation for IVF.

Authors:  Nicole D Paterson; Shu C Foong; Calvin A Greene
Journal:  J Assist Reprod Genet       Date:  2012-04-02       Impact factor: 3.412

2.  Folliculogenic factors in photoregressed ovaries: Differences in mRNA expression in early compared to late follicle development.

Authors:  Alexander K Salomon; Kathleen Leon; Melissa M Campbell; Kelly A Young
Journal:  Gen Comp Endocrinol       Date:  2018-01-06       Impact factor: 2.822

3.  Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis.

Authors:  João Batista A Oliveira; Ana Lucia Mauri; Claudia G Petersen; Anice M C Martins; João Cornicelli; Mario Cavanha; Anagloria Pontes; Ricardo L R Baruffi; José G Franco
Journal:  J Assist Reprod Genet       Date:  2006-12-29       Impact factor: 3.412

4.  Effects of luteinizing hormone and follicle stimulating hormone on the developmental competence of porcine preantral follicle oocytes grown in vitro.

Authors:  Ji Wu; Bo Xu; Wei Wang
Journal:  J Assist Reprod Genet       Date:  2007-07-17       Impact factor: 3.412

5.  Does premature luteinization or early surge of LH impair cycle outcome? Report of two successful outcomes.

Authors:  Murat Sönmezer; Aylin Pelin Cil; Cem Atabekoğlu; Sinan Ozkavukçu; Batuhan Ozmen
Journal:  J Assist Reprod Genet       Date:  2009-02-18       Impact factor: 3.412

Review 6.  The role of luteinizing hormone activity in controlled ovarian stimulation.

Authors:  N Angelopoulos; A Goula; G Tolis
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

7.  Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.

Authors:  D Carone; C Caropreso; A Vitti; R Chiappetta
Journal:  J Endocrinol Invest       Date:  2012-10-22       Impact factor: 4.256

8.  Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women and WHO group II anovulatory infertile patients.

Authors:  J Balasch; F Fábregues; J Peñarrubia; M Creus; R Vidal; R Casamitjana; D Manau; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  1998-10       Impact factor: 3.412

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.

Authors:  Bernd Th Krause; Ralf Ohlinger; Annette Haase
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.